Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
NCT ID: NCT02547532
Last Updated: 2018-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2015-09-30
2018-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serum Surfactant Protein-D as Predictor of Disease Severity in Hospitalized COPD Patients
NCT07154953
Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific
NCT03151395
The Microbiome of Sputum, Urine and Feces in Healthy Persons and Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT03755505
Evaluation Of The Lung Microbiome In NTM Bronchiectasis
NCT02779478
Prospective Cohort Study of Molecular Mechanism of Lower Respiratory Tract Microbes in Patients With AECOPD
NCT04259736
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
usual COPD
Patients meeting the diagnostic criteria for COPD and without AATD
collection of sputum
normal smokers
subjects with a history of smoking, without symptoms, without AATD and with normal lung function
collection of sputum
normal non smokers
subjects without a history of smoking, without symptoms, without AATD and with normal lung function
collection of sputum
AATD not treated
patients with COPD, with AATD and not on augmentation therapy for AATD
collection of sputum
AATD treated
patients with COPD, with AATD on augmentation therapy for AATD
collection of sputum
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
collection of sputum
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
For patients with AATD this condition will be diagnosed by laboratory tests showing low levels of AAT and genotyping of AATD-related genes.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione IRCCS Policlinico San Matteo di Pavia
OTHER
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
OTHER
Grifols Biologicals, LLC
INDUSTRY
Fondazione Salvatore Maugeri
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bruno Balbi
Head, Pulmonary Rehabilitation Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pantaleo Giannuzzi, M.D.
Role: STUDY_DIRECTOR
Fondazione Salvatore Maugeri
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Fsalvatoremaugeri
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.